AstraZeneca: gets EU approval for lung cancer drug

(CercleFinance.com) - Britain's AstraZeneca has received approval from the European Commission for Tagrisso for the first-line treatment of EGFR-mutated non-small cell lung cancer.


The EU has granted marketing authorisation for Tagrisso as monotherapy for the treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, the drugmaker said late on Friday.

According to preliminary overall survival data, the drug led to a 37% reduction in the risk of death, prompting the company to say that Tagrisso offers a "potential new standard of care."

The approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Copyright (c) 2018 CercleFinance.com. All rights reserved.